We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current FATE market cap is 191.37M. The company's latest EPS is USD -1.4130 and P/E is -1.20.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 933k | 1.94M | 1.68M | 1.93M | 6.77M |
| Operating Income | -62.57M | -51.28M | -48.08M | -51.07M | -45.08M |
| Net Income | -52.76M | -45.17M | -44.12M | -48M | -38.43M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10.68M | 31.43M | 55.85M | 96.3M | 63.53M |
| Operating Income | -100.73M | -128.09M | -216.99M | -308.39M | -190.51M |
| Net Income | -98.15M | -173.39M | -212.15M | -281.72M | -160.93M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 584.76M | 543.79M | 506.22M | 569.89M | 528.82M |
| Total Liabilities | 147M | 141.01M | 137.8M | 143.78M | 131.84M |
| Total Equity | 437.76M | 402.78M | 368.42M | 426.12M | 396.98M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 302.27M | 622.46M | 921.46M | 705.56M | 506.22M |
| Total Liabilities | 57.52M | 238.01M | 242.62M | 221.62M | 137.8M |
| Total Equity | 244.76M | 384.45M | 678.84M | 483.94M | 368.42M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -57.35M | -95.63M | -132.26M | -33.35M | -65.66M |
| Investing | 42.51M | 67.31M | 112.67M | 17.31M | -36.06M |
| Financing | 265k | 265k | 85k | 95.49M | 96.76M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -83.18M | -39.23M | -162.87M | -248.21M | -132.26M |
| Investing | -157.45M | -161.08M | -324.02M | 166.75M | 112.67M |
| Financing | 149.93M | 282.84M | 453.13M | 9.21M | 85k |
| Market Cap | 191.37M |
| Price to Earnings Ratio | -1.20 |
| Price to Sales Ratio | 3.03 |
| Price to Cash Ratio | 4.6 |
| Price to Book Ratio | 0.52 |
| Dividend Yield | - |
| Shares Outstanding | 113.89M |
| Average Volume (1 week) | 3.85M |
| Average Volume (1 Month) | 4.1M |
| 52 Week Change | -48.30% |
| 52 Week High | 8.83 |
| 52 Week Low | 1.59 |
| Spread (Intraday) | 1.38 (46%) |
| Company Name | Fate Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.fatetherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
